Valuation dashboard for Nuvation Bio Inc. (NUVB) with P/E N/A, P/B 7.68, EV/EBITDA -15.36 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
Nuvation Bio Inc. functions as a clinical-stage biopharmaceutical enterprise committed to discovering and advancing therapeutic solutions for oncological conditions. Its foremost experimental compound, NUV-422, is a small molecule designed to inhibit cyclin-dependent kinases (CDK)2, CDK4, and CDK6.
Valuation Ratios
| Price / Book | 7.68 |
| EV / EBITDA | -15.36 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NUVB | Nuvation Bio Inc. | $2.0B | 7.68 | -66.9% | |
| EWTX | Edgewise Therapeutics, Inc. | $4.9B | 10.73 | ||
| GPCR | Structure Therapeutics Inc. | $2.0B | 1.92 | -16.9% | |
| CLDX | Celldex Therapeutics, Inc. | $2.6B | 4.25 | -52.4% | |
| AUPH | Aurinia Pharmaceuticals Inc. | $2.2B | 7.19 | 3.59 | 59.0% |
| OCUL | Ocular Therapeutix, Inc. | $2.3B | 4.41 | -59.9% | |
| ABCL | AbCellera Biologics Inc. | $3.5B | 3.98 | -17.5% |
Price
| Price | $5.78 |
| Market Cap | $2.0B |
| Exchange | NYSE |
| Country | US |
Profitability
| Return on Equity | -66.93% |
| Return on Invested Capital | -40.96% |
| Return on Assets | -34.40% |
| Gross Margin | 93.94% |
| Operating Margin | -81.00% |
| Net Margin | -88.19% |
Related companies: ABCL · AUPH · CLDX · EWTX · GPCR · JANX · OCUL
Explore sector: Healthcare · Biotechnology
More sections of NUVB: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks